Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases (Q33382828)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

Raphael A Itzykson

object named as

R Itzykson

1

0 references

21

object named as

P Fenaux

1 reference

Europe PubMed Central

26 July 2017

Groupe Francophone des Myelodysplasies (GFM)

23

object named as

Groupe Francophone des Myelodysplasies (GFM)

1 reference

Europe PubMed Central

26 July 2017

Odile Beyne-Rauzy

8

object named as

O Beyne-Rauzy

1 reference

Europe PubMed Central

26 July 2017

author name string

S Ayari

2

1 reference

Europe PubMed Central

26 July 2017

D Vassilief

3

1 reference

Europe PubMed Central

26 July 2017

E Berger

4

1 reference

Europe PubMed Central

26 July 2017

B Slama

5

1 reference

Europe PubMed Central

26 July 2017

N Vey

6

1 reference

Europe PubMed Central

26 July 2017

F Suarez

7

1 reference

Europe PubMed Central

26 July 2017

A Guerci

9

1 reference

Europe PubMed Central

26 July 2017

S Cheze

10

1 reference

Europe PubMed Central

26 July 2017

X Thomas

11

1 reference

Europe PubMed Central

26 July 2017

A Stamatoullas

12

1 reference

Europe PubMed Central

26 July 2017

M Gardembas

13

1 reference

Europe PubMed Central

26 July 2017

F Bauduer

14

1 reference

Europe PubMed Central

26 July 2017

A Kolb

15

1 reference

Europe PubMed Central

26 July 2017

M C Chaury

16

1 reference

Europe PubMed Central

26 July 2017

L Legros

17

1 reference

Europe PubMed Central

26 July 2017

G Damaj

18

1 reference

Europe PubMed Central

26 July 2017

F Chermat

19

1 reference

Europe PubMed Central

26 July 2017

F Dreyfus

20

1 reference

Europe PubMed Central

26 July 2017

L Ades

22

1 reference

Europe PubMed Central

26 July 2017

publication date

8 January 2009

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

23

1 reference

Europe PubMed Central

26 July 2017

4

1 reference

Europe PubMed Central

26 July 2017

673-678

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1038/leu.2008.362

0 references

Supportive care, growth factors, and new therapies in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Anemia in the elderly: how should we define it, when does it matter, and what can be done?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

The role of lenalidomide in the management of myelodysplasia with del 5q.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Regulation of hematopoiesis by retinoid signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Early mitochondrial alterations in ATRA-induced cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all- trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all- trans -retinoic acid, granulocyte colony-stimulating factor, erythropoietin and α-tocopherol

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

21 January 2018

All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

7 January 2021

based on heuristic

inferred from DOI database lookup

Retinoids in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.362

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2008.362

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33382828&oldid=1743983176"